EMA Environmental Risk Assessment Guidelines: What Pharmaceutical Companies Need to Know
The EMA environmental risk assessment guidelines provide an important regulatory framework for evaluating the potential environmental impact of human medicinal products. Pharmaceutical companies must consider how active pharmaceutical ingredients may affect aquatic and terrestrial ecosystems following product use. Understanding these requirements is essential for preparing compliant marketing authorisation applications and supporting responsible pharmaceutical development.
Understanding Environmental Risk Assessment (ERA)
An Environmental Risk Assessment (ERA) evaluates the potential risks associated with the use of a medicinal product and its active substances. The European Medicines Agency (EMA) requires an ERA as part of marketing authorisation applications for human medicinal products, irrespective of the authorisation procedure.
The current guideline, Revision 1 (EMEA/CHMP/SWP/4447/00 Rev. 1), became effective on 1 September 2024. It provides updated scientific recommendations for assessing environmental exposure, substance behaviour, and potential ecological toxicity.
Key Requirements Under EMA Environmental Risk Assessment Guidelines
The assessment follows a structured approach involving two main phases. Phase I estimates environmental exposure using the predicted environmental concentration (PEC). If the applicable assessment criteria indicate potential environmental concern, further investigation through Phase II is required.
Phase II involves detailed investigations of the active substance’s physicochemical properties, environmental fate, and ecotoxicological effects. Companies may need to evaluate impacts on surface water, sediment, soil, groundwater, and sewage treatment processes.
The guideline also addresses persistence, bioaccumulation, and toxicity through PBT and vPvB assessments. Special consideration is given to substances such as antibiotics and endocrine-active substances because of their specific environmental concerns.
How Pharmaceutical Companies Can Ensure Compliance
Pharmaceutical companies should establish a systematic approach to ERA preparation, including reliable scientific data collection, appropriate study selection, documented risk assessments, and justified conclusions. Environmental data should be reviewed when changes in product use or new scientific information may affect previous assessments.
For regulatory submissions, the ERA should be scientifically justified, clearly documented, and appropriately integrated into the marketing authorisation dossier.
Understanding the EMA environmental risk assessment guidelines helps pharmaceutical companies address regulatory expectations while supporting environmental protection. A well-prepared ERA strengthens regulatory submissions and demonstrates a responsible approach to pharmaceutical product development.